Fentanyl intranasal - Takeda

Drug Profile

Fentanyl intranasal - Takeda

Alternative Names: Instanyl

Latest Information Update: 29 May 2012

Price : $50

At a glance

  • Originator Nycomed
  • Developer Takeda Pharmaceuticals International GmbH
  • Class General anaesthetics; Opioid analgesics; Piperidines; Small molecules
  • Mechanism of Action Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Cancer pain

Most Recent Events

  • 08 Aug 2013 Biomarkers information updated
  • 27 Mar 2012 Nycomed is now called Takeda Pharmaceuticals International GmbH
  • 29 Feb 2012 Takeda completes a phase I trial in Healthy volunteers in Germany (NCT01497288)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top